Aerie Pharmaceuticals to Participate in the Bank of America Securities 2021 Healthcare Conference

Rhea-AI Summary

Aerie Pharmaceuticals (NASDAQ: AERI) announced that Vicente Anido, Jr., Ph.D., Chairman and CEO, will present at the Bank of America Securities 2021 Healthcare Conference on May 12, 2021, at 9:30 a.m. ET. The discussion will provide an overview of Aerie and a business update. The presentation will be webcast live on Aerie’s website, with a replay available for 10 business days. Aerie focuses on developing first-in-class therapies for open-angle glaucoma and ocular diseases, including their products Rhopressa^® and Rocklatan^®.

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Bank of America Securities 2021 Healthcare Conference on Wednesday, May 12, 2021 at 9:30 a.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.

The fireside discussion will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com. A replay of the fireside discussion will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa^® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa^®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan^® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa^® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan^®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210506005062/en/

FAQ

What will Vicente Anido discuss at the Bank of America Securities Healthcare Conference?

Vicente Anido will provide an overview of Aerie Pharmaceuticals and a business update during the conference.

When is Aerie Pharmaceuticals presenting at the Bank of America Securities Healthcare Conference?

Aerie Pharmaceuticals will present on May 12, 2021, at 9:30 a.m. Eastern Time.

How can I watch Aerie's presentation at the Healthcare Conference?

The presentation will be webcast live on Aerie’s website and will be available for replay for 10 business days.

What is the focus of Aerie Pharmaceuticals' product development?

Aerie Pharmaceuticals focuses on developing therapies for open-angle glaucoma and ocular surface diseases.

What are the key products of Aerie Pharmaceuticals?

Aerie Pharmaceuticals' key products include Rhopressa^® and Rocklatan^®.